Epidemiology of rotavirus in infants and protection against symptomatic illness afforded by primary infection and vaccination

Vaccine

Volumn 17, Issue 7-8, 1999, Pages 745-753

  Mrukowicz, Jacek Z ^a   Thompson, Juliette ^a   Reed, George W ^a   Tollefson, Sharon J ^a   Kobayashi, Masaaki ^a   Araki, Kozuko ^a   Wright, Peter F ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Epidemiology; Rotavirus; Vaccines

Indexed keywords

ROTAVIRUS VACCINE;

ANTIBODY TITER; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; GASTROENTERITIS; HUMAN; IMMUNITY; INFANT; INFECTION RESISTANCE; INFECTION RISK; NORMAL HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; ROTAVIRUS; SEROPREVALENCE; SEROTYPE; VIRUS INFECTION;

ANTIBODIES, VIRAL; FEMALE; GASTROENTERITIS; HUMANS; IMMUNITY, NATURAL; IMMUNOGLOBULIN G; INFANT; MALE; PROSPECTIVE STUDIES; ROTAVIRUS; ROTAVIRUS INFECTIONS; VIRAL VACCINES;

EID: 0033605089     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00258-8     Document Type: Article

References (47)

1. Blacklow N.R., Greenberg H.B. Viral gastroenteritis. New England Journal of Medicine. 325:1991;252-264.
2. Kapikian A., Chanock R.M., Rotaviruses. In: Fields B.N., Knipe D.M., editors. Virology. IL: Raven Press, 1996. p. 1657-1708.
3. Bern C., Martines J., de Zoysa I., Glass R.I. The magnitude of the global problem of diarrheal disease: a ten years update. Bulletin of the World Health Organization. 70:1992;705-714.
4. Prospects for immunizing against rotavirus. In: Institute of Medicine. New vaccine development: establishing priorities, vol. 2. Diseases of importance in developing countries. Washington, DC: National Academy Press 1986. p. 312.
5. Glass R.l., Lew J.F., Gangarosa R.E., LeBaron C.W., Ho M.-S. Estimates of morbidity and mortality rates for diarrheal diseases in American children. Journal of Pediatrics. 118:1991;S27-S33.
6. Jin S., Kilgore P.E., Holman R.C., Clarke M.J., Gangarosa E.J., Glass R.I. Trends in hospitalizations for diarrhea in United States children from 1979 through 1992: estimates of the morbidity associated with rotavirus. Pediatric Infectious Disease Journal. 15:1996;397-404.
7. Bartlett A.V., Reves R.R., Pickering L.K. Rotavirus in infant-toddler day care centers: epidemiology relevant to disease control strategies. Journal of Pediatrics. 113:1988;435-441.
8. Chiba S., Yokoyama T., Nakata S., Morita Y., Urasawa T., Taniguchi K., Urasawa S., Nakao T. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet. 2:1986;417-421.
9. US Rotavirus Efficacy Group, Ward R.L., Bernstein D.I. Protection against rotavirus disease after natural infection. Journal of Infectious Diseases. 169:1994;900-904.
10. Velazquez F.R., Matson D.O., Calva J.J., Guerrero M.L., Morrow A.L., Carter-Campbell S., Glass R.I., Estes M.K., Pickering L.K., Ruiz-Palacids G.M. Rotavirus infection in infants as protection against subsequent infections. New England Journal of Medicine. 335:1996;1022-1028.
11. US Rotavirus Vaccine Efficacy Group, Bernstein D.I., Glass R.I., Rodgers G., Davidson B.L., Sack D.A. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA. 273:1995;1191-1196.
12. Wright P.F., Tajima T., Thompson J., Kokubun K., Kapikian A.Z., Karzon D.T. Candidate rotavirus vaccine (rhesus rotavirus strain) in children: an evaluation. Pediatrics. 80:1987;473-480.
13. Tajima T., Thompson J., Wright P.F., Kondo Y., Tollefson S.J., King J., Kapikian A.Z. Evaluation of a reassortant rhesus rotavirus vaccine in young children. Vaccine. 8:1990;70-74.
14. Wright P.F., King J., Araki K., Kondo Y., Thompson J., Tollefson S.J., Kobayashi M., Kapikian A.Z. Simultaneous administration of two human-rhesus rotavirus reassortant strains of VP7 serotype 1 and 2 specificity to infants and young children. Journal of Infectious Disease. 164:1991;271-276.
15. Flores J., Perez-Schael I., Gonzalez M., Garcia D., Perez M., Daoud W., Cunto W., Chanock R.M., Kapikian A.Z. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet. 1:1987;882-884.
16. Madore H.P., Christy C., Pichichero M., Long C., Pincus P., Vosefsky D., Kapikian A.Z., Dolin R. Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. Journal of Infectious Disease. 166:1992;235-243.
17. Wyatt R.G., Greenberg H.B., James W.D., Pittman A.L., Kalica A.R., Flores J., Chanock R.M., Kapikian A.Z. Definition of human serotypes by plaque reduction assay. Infection and Immunity. 37:1982;110-115.
18. Wyatt R.G., James H.D., Pittman A.L., Hoshino Y., Greenberg H.B., Kalica A.R., Flores J., Kapikian A.Z. Direct isolation in cell culture of human rotaviruses and their characterization into four serotypes. Journal of Clinical Microbiology. 18:1983;310-317.
19. Hoshino Y., Wyatt R.G., Greenberg H.B., Flores J., Kapikian A. Serotypic similarity and diversity of rotaviruses of mammalian and avian origin as studied by plaque-reduction neutralization. Journal of Infectious Disease. 149:1984;694-702.
20. Ruuska T., Vesikari T., Delem A., Andre F.E., Beards G.M., Flewett T.H. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. Scandinavian Journal of Infectious Disease. 22:1990;269-278.
21. Vesikari T., Isolauri E., Delem A., d'Hondt E., Andre F.E., Beards G.M., Flewett T.H. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. Journal of Pediatrics. 107:1985;189-194.
22. De Champs C., Laveran H., Peigue-Lafeuille H., Chambon M., Demeocq F., Gaul J., Beytout D. Sequential rotavirus infections: characterization of serotypes and electropherotypes. Research in Virology. 142:1991;39-45.
23. Mata L., Simhon A., Urrutia J.J., Kronmal R.A., Fernandez R., Garcia B. Epidemiology of rotaviruses in a cohort of 45 Guatamalan Mayan Indian children observed from birth to the age of three years. Journal of Infectious Disease. 148:1983;452-461.
24. Bishop R.F., Barnes G.L., Cipriani E., Lund J.S. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. New England Journal of Medicine. 309:1983;72-76.
25. Bernstein D.I., Sander D.S., Smith V.E., Schiff G.M., Ward R.L. Protection from rotavirus reinfection: 2-year prospective study. Journal of Infectious Disease. 161:1991;277-283.
26. Ho M., Glass R.I., Pinsky P.F., Anderson L.J. Rotavirus as a cause of diarrheal morbidity and mortality in the United States. Journal of Infectious Disease. 158:1988;1112-1116.
27. Rotavirus Study Group, LeBaron C.W., Lew J., Glass R.I., Weber J.M., Ruiz-Palacios G.M. Annual rotavirus epidemic patterns in North America. JAMA. 264:1990;983-988.
28. Rodriguez W.J., Kim H.W., Brandt C.D., Schwartz R.H., Gardner M.K., Jeffries B., Parrott R.H., Kaslow R.A., Smith J.I., Kapikian A.Z. Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations. Pediatric Infectious Disease Journal. 6:1987;170-176.
29. O'Ryan M.L., Matson D.O., Estes M.K., Pickering L.K. Antirotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. Journal of Infectious Disease. 169:1994;504-511.
30. Ryder R.W., Singh N., Reeves W.C., Kapikian A.Z., Greenberg H.B., Sack R.B. Evidence of immunity induced by naturally acquired rotavirus and Norwalk virus infection on two remote Panamanian islands. Journal of Infectious Disease. 151:1985;99-105.
31. Clemens J., Ward J., Rao M., Sack D.A., Knowlton D.R., Van Loon F.P.L., Huda S., McNeal M., Ahmed F., Schiff G. Seroepidemiologic evaluation of antibodies to rotavirus as correlates of the risk of clinically significant rotavirus diarrhea in rural Bangladesh. Journal of Infectious Disease. 165:1992;161-165.
32. US Rotavirus Vaccine Efficacy Group, Ward R.L., Bernstein D.I. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. Vaccine. 13:1995;1226-1232.
33. Richardson S.C., Grimwood K., Bishop R. Analysis of homotypic and heterotypic serum immune responses to rotavirus proteins following primary rotavirus infections by using the radioimmunoprecipitation technique. Journal of Clinical Microbiology. 31:1993;377-385.
34. Coulson B.S., Tursi J.M., McAdam W.J., Bishop R.F. Derivation of neutralizing monoclonal antibodies to human rotavirus and evidence that an immunodominant site is shared between serotypes 1 and 3. Virology. 154:1986;302-312.
35. Green K.Y., Kapikian A.Z. Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers. Journal of Virology. 66:1992;548-553.
36. Gorziglia M., Larralde G., Kapikian A.Z., Chanock R.M. Antigenic relationships among human rotaviruses as determined by outer capsid VP4. Proceedings of the National Academy of Science. 87:1990;7155-7159.
37. Mackow E.R., Vo P.T., Broome R., Bass D., Greenberg H.B. Immunization with baculovirus-expressed VP4 protein passively protects against simian and murine rotavirus challenge. Journal of Virology. 64:1990;1698-1703.
38. Green K.Y., Taniguchi K., Mackow E.R., Kapikian A.Z. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implication for vaccine development. Journal of Infectious Disease. 161:1990;667-669.
39. Ward R.L., Sander D.S., Schiff G.M., Bernstein D.I. Effect of vaccination on serotype specific antibody responses in infants administered WC3 bovine rotavirus before or after a natural rotavirus infection. Journal of Infectious Disease. 162:1990;1298-1303.
40. Pichichero M.E., Losonsky G.A. Asymptomatic infections due to wild-type rotavirus may prime for a heterotypic response to vaccination with rhesus rotavirus. Journal of Infectious Disease. 16:1993;86-92.
41. Gothefors L., Wadell G., Juto P., Taniguchi K., Kapikian A.Z., Glass R.I. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. Journal of Infectious Disease. 159:1989;753-757.
42. Clark H.F., Borian R.E., Bell L.M., Modesto K., Gouvea V., Plotkin S.A. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. Journal of Infectious Disease. 158:1988;570-587.
43. Treanor J.J., Clark H.F., Pichichero M., Christy C., Gouvea V., Shrager D., Palazzo S., Offit P. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatric Infectious Disease Journal. 14:1995;301-307.
44. United States Rotavirus Vaccine Efficacy Group, Rennels M.B., Glass R.I., Dennehy P.H., Bernstein D.I., Pichichero M.E., Zito E.T., Mack M.E., Davidson B.L., Kapikian A.Z. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines: report of the national multicenter trial. Pediatrics. 97:1996;7-13.
45. Perez-Schael I., Guntinas M.J., Perez M., Pagone V., Rojas A.M., Gonzalez R., Cunto W., Hoshino Y., Kapikian A.Z. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. New England Journal of Medicine. 337:1997;1181-1187.
46. Joensuu J., Koskenniemi E., Pang X.-L., Vesikari T. Randomised placebo controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet. 350:1997;1205-1209.
47. Santosham M., Moulton L.H., Reid R., Croll J., Weatherholt R., Ward R., Forro J., Zito E., Mack M., Brenneman G., Davidson B.L. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in native American populations. Journal of Pediatrics. 131:1997;632-638.